MX2022002116A - Peptidos para tratar la atrofia muscular. - Google Patents
Peptidos para tratar la atrofia muscular.Info
- Publication number
- MX2022002116A MX2022002116A MX2022002116A MX2022002116A MX2022002116A MX 2022002116 A MX2022002116 A MX 2022002116A MX 2022002116 A MX2022002116 A MX 2022002116A MX 2022002116 A MX2022002116 A MX 2022002116A MX 2022002116 A MX2022002116 A MX 2022002116A
- Authority
- MX
- Mexico
- Prior art keywords
- peptides
- muscle
- subjects
- muscle atrophy
- atrophy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
El solicitante ha descubierto una serie de péptidos que son capaces de fosforilar la proteína ribosómica S6 (rpS6) en un rango de concentraciones en ensayos celulares in vitro de forma dependiente de la dosis. RPS6 es un sustrato clave para las proteínas quinasas y es fosforilada por factores de crecimiento y mitógenos durante el crecimiento y la división celular. Este es un paso clave en la síntesis de nuevas proteínas en el tejido muscular esquelético. Los péptidos descritos tienen también la capacidad de reducir la expresión de los transcritos de ARNm (TRIM63 y FBXO32) que están directamente relacionados con el aumento de la degradación de las proteínas, lo que resulta en la atrofia progresiva del músculo esquelético. Además, el aumento de la atrofia muscular está relacionado con el aumento sistémico del TNFa circulante. Los péptidos descritos en el presente documento también conducen a la reducción de la expresión de TNFa en las células inmunes circulantes. Los péptidos se pueden utilizar para promover el crecimiento muscular y la salud muscular en sujetos que presentan atrofia muscular, por ejemplo, sujetos de edad avanzada, personas físicamente inactivas y sujetos que tienen indicaciones caracterizadas por la atrofia muscular (es decir, esclerosis múltiple y poliomielitis).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19192689 | 2019-08-20 | ||
PCT/EP2020/072937 WO2021032650A1 (en) | 2019-08-20 | 2020-08-14 | Peptides for treating muscle atrophy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022002116A true MX2022002116A (es) | 2022-03-17 |
Family
ID=67659544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022002116A MX2022002116A (es) | 2019-08-20 | 2020-08-14 | Peptidos para tratar la atrofia muscular. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220287347A1 (es) |
EP (2) | EP4017518A1 (es) |
JP (1) | JP2022545265A (es) |
KR (1) | KR20220103695A (es) |
CN (1) | CN114650834A (es) |
AU (1) | AU2020334196A1 (es) |
BR (1) | BR112022002727A2 (es) |
CA (1) | CA3147981A1 (es) |
MX (1) | MX2022002116A (es) |
WO (1) | WO2021032650A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023096232A1 (ko) * | 2021-11-25 | 2023-06-01 | (주)네오크레마 | 신규 펩티드 및 이의 용도 |
WO2023096233A1 (ko) * | 2021-11-25 | 2023-06-01 | (주)네오크레마 | 신규 펩티드 및 이의 용도 |
KR20230170490A (ko) * | 2022-06-10 | 2023-12-19 | (주)케어젠 | 근육 손실 저해 및 근육량 증진 활성을 갖는 펩타이드 및 이의 용도 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3654090A (en) | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
US5972650A (en) | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
EP1033405A3 (en) * | 1999-02-25 | 2001-08-01 | Ceres Incorporated | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby |
US20110214206A1 (en) * | 1999-05-06 | 2011-09-01 | La Rosa Thomas J | Nucleic acid molecules and other molecules associated with plants |
US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
EP1392859B1 (en) | 2001-01-16 | 2006-05-10 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
CN1832755A (zh) | 2003-05-23 | 2006-09-13 | 佩斯特卡生物医疗实验室公司 | 使用干扰素治疗严重急性呼吸综合征及其他病毒感染 |
US20070053845A1 (en) | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
CN101102784A (zh) * | 2005-01-13 | 2008-01-09 | 雷金纳克斯生物制药公司 | 对由神经退行性疾病、肌肉退行性疾病、或神经-肌肉退行性疾病所致的组织退化、伤害或损伤进行治疗或预防的方法、或对受到所述疾病的不利影响的组织进行恢复的方法 |
US8105572B2 (en) | 2007-05-18 | 2012-01-31 | New York University | Method of treating tuberculosis with interferons |
ES2522615T3 (es) | 2007-06-04 | 2014-11-17 | Regeneron Pharmaceuticals, Inc. | Regiones de expresión y estabilidad potenciadas |
EP2050437A1 (en) | 2007-10-15 | 2009-04-22 | Laboratoires SMB | Improved pharmaceutical dry powder compositions for inhalation. |
ES2397890B1 (es) | 2011-03-25 | 2014-02-07 | Lipotec, S.A. | Péptidos útiles en el tratamiento y/o cuidado de la piel y/o mucosas y su uso en composiciones cosméticas o farmacéuticas. |
EP2771349B1 (en) * | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
KR20170002846A (ko) * | 2015-06-30 | 2017-01-09 | (주)아모레퍼시픽 | 콩잎 추출물을 유효성분으로 함유하는 근질환 억제 및 예방용 조성물 |
EP3118215A1 (en) * | 2015-07-16 | 2017-01-18 | Nuritas Limited | Anti-inflammatory peptides, and uses thereof |
EP3117831A1 (en) * | 2015-07-16 | 2017-01-18 | Nuritas Limited | Peptides for use in promoting transport of glucose into skeletal muscle |
EP3118216A1 (en) * | 2015-07-16 | 2017-01-18 | Nuritas Limited | Cellular growth and proliferation promoting peptides, and uses thereof |
AU2018378812A1 (en) * | 2017-12-06 | 2020-07-09 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
-
2020
- 2020-08-14 AU AU2020334196A patent/AU2020334196A1/en active Pending
- 2020-08-14 US US17/635,796 patent/US20220287347A1/en active Pending
- 2020-08-14 WO PCT/EP2020/072937 patent/WO2021032650A1/en unknown
- 2020-08-14 BR BR112022002727A patent/BR112022002727A2/pt unknown
- 2020-08-14 EP EP20767974.7A patent/EP4017518A1/en active Pending
- 2020-08-14 KR KR1020227009063A patent/KR20220103695A/ko unknown
- 2020-08-14 CN CN202080070699.2A patent/CN114650834A/zh active Pending
- 2020-08-14 MX MX2022002116A patent/MX2022002116A/es unknown
- 2020-08-14 JP JP2022511277A patent/JP2022545265A/ja active Pending
- 2020-08-14 CA CA3147981A patent/CA3147981A1/en active Pending
- 2020-08-14 EP EP23156938.5A patent/EP4218787A3/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220287347A1 (en) | 2022-09-15 |
EP4017518A1 (en) | 2022-06-29 |
BR112022002727A2 (pt) | 2022-08-23 |
JP2022545265A (ja) | 2022-10-26 |
CA3147981A1 (en) | 2021-02-25 |
EP4218787A2 (en) | 2023-08-02 |
WO2021032650A1 (en) | 2021-02-25 |
KR20220103695A (ko) | 2022-07-22 |
EP4218787A3 (en) | 2023-12-20 |
AU2020334196A1 (en) | 2022-03-03 |
CN114650834A (zh) | 2022-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022002116A (es) | Peptidos para tratar la atrofia muscular. | |
Zhang et al. | Irisin exerts dual effects on browning and adipogenesis of human white adipocytes | |
Londhe et al. | Classical NF-κB metabolically reprograms sarcoma cells through regulation of hexokinase 2 | |
Goldberg et al. | IL-33 causes thermogenic failure in aging by expanding dysfunctional adipose ILC2 | |
Baum et al. | Micronutrient status in relationship to mortality in HIV-1 disease | |
Coelho et al. | Metabolic reprogramming in thyroid carcinoma | |
Choi et al. | Fisetin inhibits osteoclast differentiation via downregulation of p38 and c-Fos-NFATc1 signaling pathways | |
Salama et al. | Enhanced supply of methionine or arginine alters mechanistic target of rapamycin signaling proteins, messenger RNA, and microRNA abundance in heat-stressed bovine mammary epithelial cells in vitro | |
KR102245702B1 (ko) | 셀렌을 포함하는 조성물 및 미토콘드리아 기능장해와 관련된 질병 또는 상태의 치료와 예방을 위한 이의 용도 | |
Peters et al. | Dose-dependent effects of leucine supplementation on preservation of muscle mass in cancer cachectic mice | |
MX339068B (es) | Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias. | |
EP1670450B8 (en) | Pharmaceutical compositions and method of using levodopa and carbidopa | |
Lin et al. | Interleukin‐17 regulates the expressions of RANKL and OPG in human periodontal ligament cells via TRAF 6/TBK 1‐JNK/NF‐κB pathways | |
DE60130464D1 (de) | Pre-adipose zelllinien | |
EA202191508A1 (ru) | Размножение естественных клеток-киллеров и клеток ilc3 с использованием новых ароматических соединений | |
Ceci et al. | Skeletal muscle differentiation: role of dehydroepiandrosterone sulfate | |
Wang et al. | Dehydroabietic acid reverses TNF-α-induced the activation of FOXO1 and suppression of TGF-β1/Smad signaling in human adult dermal fibroblasts | |
MX2020004397A (es) | Uso de suplementos de aminoacidos para mejorar la sintesis de proteinas musculares. | |
Salles et al. | Fast digestive, leucine‐rich, soluble milk proteins improve muscle protein anabolism, and mitochondrial function in undernourished old rats | |
Wen et al. | Pyrroloquinoline quinone attenuates isoproterenol hydrochloride‑induced cardiac hypertrophy in AC16 cells by inhibiting the NF‑κB signaling pathway | |
Prieto-Hontoria et al. | Lipoic acid inhibits adiponectin production in 3T3-L1 adipocytes | |
AU2020344620A8 (en) | Implant comprising first and second sets of pillars for attaching a tendon or ligament to a hard tissue | |
MX2021010218A (es) | Inhibidor de la interaccion proteina-proteina wdr5 basado en anilina, metodo para preparar el mismo y uso del mismo. | |
Yang et al. | Effects of long-term supplementation of blue-green algae on lipid metabolism in C57BL/6J mice | |
WO2019066617A3 (ko) | 항 c-met 항체 및 이의 용도 |